Clinically, the relevance of this pathway is underscored by evidence that IL-6 blockade with tocilizumab lowers bone resorption and preserves bone mineral density in inflammatory conditions such as rheumatoid arthritis [35]. Here, IL6 is linked to rheumatoid arthritis.